



OPTISCAN IMAGING LIMITED
ABN 81 077 771 987

For all enquiries:



Phone:
(within Australia) 1300 850 505
(outside Australia) +61 3 9415 4000

5 September 2025

Dear Shareholder

OPTISCAN IMAGING LIMITED – PRO-RATA RENOUNCEABLE RIGHTS ISSUE

As announced on 27 August 2025, Optiscan Imaging Limited (ACN 077 771 987) (**Optiscan** or the **Company**) is undertaking a pro rata renounceable rights issue of one (1) fully paid ordinary share in the capital of the Company (**Share**) for every four (4) Shares held at an issue price of \$0.085 per Share to raise up to approximately \$17,750,992 (**Offer**).

The Company lodged a prospectus for the Offer (**Prospectus**) with ASIC and ASX on 27 August 2025.

The Offer is fully underwritten by Peters Investments Pty Ltd (**Underwriter**). There is no underwriting fee payable to the Underwriter.

The Company intends to apply the funds raised from the Offer (less expenses) to undertake necessary clinical studies, testing and certification of its clinical medical devices (InVue®, InForm™, InSpecta™), submission of necessary documentation to achieve US regulatory approvals for these devices, furthering the development of the Company's flexible endomicroscope, preparation of commercialisation plans for said devices, and for general working capital. For further specifics of the use of funds please refer to section 3.1 of the Prospectus.

Following completion of the Offer, assuming any shortfall is subsequently placed and the full subscription is raised, the Company will have issued approximately 208,835,201 Shares resulting in total Shares on issue of 1,044,176,004.

Ineligible shareholders

A Shareholder who has a registered address outside Australia, New Zealand and Singapore (**Ineligible Shareholder**) will not be eligible to participate in the Offer.

You are not eligible to participate in the Offer and you will not be sent a copy of the Prospectus. This decision has been made pursuant to Listing Rule 7.7.1(a) of the ASX Listing Rules after taking into consideration the costs of complying with legal and regulatory requirements in jurisdictions outside of Australia, New Zealand and Singapore compared with the small number of Ineligible Shareholders and the number and value of Shares to which they would otherwise be entitled.

The Company has appointed Canaccord Genuity (Australia) Limited (ACN 075 071 466) (AFSL 234666) (**Nominee**) as nominee to sell the rights to subscribe for Shares pursuant to the Prospectus (**Entitlements**) to which Ineligible Shareholders are entitled. The Nominee will have the absolute and sole discretion to determine the timing and price at which the Entitlements may be sold and the manner of any such sale.

The proceeds of the sale of these Entitlements will firstly be applied against the expenses of such sale, including brokerage, and any balance will accrue to the relevant Ineligible Shareholders as described below.

The net proceeds of the sale of these Entitlements will then be forwarded by the Company as soon as practicable to the Ineligible Shareholders, in proportion to their share of such Entitlements (after deducting brokerage commission and other expenses). If any such net proceeds of sale are less than the reasonable costs that would be incurred by the Company for distributing those proceeds, such proceeds may be retained by the Company.

Notwithstanding that the Nominee may sell Entitlements, Ineligible Shareholders may nevertheless receive no net proceeds if the costs of the sale are greater than the sale proceeds.

There is no guarantee that the Nominee will be able to sell Entitlements of Ineligible Shareholders on ASX and Ineligible Shareholders may receive no value for the Entitlements. Both the Company and the Nominee take no responsibility for the outcome of the sale of such Entitlements or the failure to sell such Entitlements.

If you have any queries concerning the Offer, please contact your financial adviser or the Information Line on 1300 850 505 (within Australia), +61 3 9415 4000 (outside of Australia) Monday to Friday, 8:30am to 5:00pm (AEST), until the Closing Date.

Yours sincerely



Camile Farah
Managing Director and Chief Executive Officer
Optiscan Imaging Limited